Reid P R, Greene H L, Varghese P J
Br Heart J. 1977 Dec;39(12):1353-60. doi: 10.1136/hrt.39.12.1353.
Four patients with supraventricular tachycardia associated with the Wolff-Parkinson-White syndrome were refractory to conventional pharmacological therapy and received aprindine hydrochloride intravenously and orally. Electrophysiological studies disclosed that intravenous aprindine caused increased refractoriness and slowed conduction in the atria, atrioventricular node, ventricles, and accessory pathway. The ability to induce supraventricular tachycardia with timed atrial and ventricular premature stimuli was totally abolished in all 4 patients after intravenous aprindine. Oral aprindine therapy, twice daily thereafter, provided symptomatic relief of the supraventricular tachycardia without significant side effects. Aprindine is useful in the management of supraventricular tachycardia associated with Wolff-Parkinson-White and may offer significant advantages over currently available therapy.
4例伴有预激综合征的室上性心动过速患者对传统药物治疗无效，接受了盐酸阿普林定静脉及口服治疗。电生理研究显示，静脉注射阿普林定可使心房、房室结、心室及旁路的不应期延长，传导减慢。静脉注射阿普林定后，所有4例患者利用定时心房和心室早搏刺激诱发室上性心动过速的能力完全消失。此后每日2次口服阿普林定治疗，可使室上性心动过速症状缓解，且无明显副作用。阿普林定对治疗伴有预激综合征的室上性心动过速有效，可能比现有治疗方法具有显著优势。
